AM-2201 (1-(5-fluoropentyl)-3-(1-naphthoyl)indole) is a recreational designer drug that acts as a potent but nonselective full agonist for the cannabinoid receptor. It is part of the AM series of cannabinoids discovered by Alexandros Makriyannis at Northeastern University.
Convulsions have been reported including at doses as low as 10 mg.
AM-2201 is a full agonist for cannabinoid receptors. Affinities are: with a K<sub>i</sub> of 1.0 nM at CB<sub>1</sub> and 2.6 nM at CB<sub>2</sub>. The 4-methyl functional analog MAM-2201 probably has similar affinities. AM-2201 has an EC<sub>50</sub> of 38 nM for human CB<sub>1</sub> receptors, and 58 nM for human CB<sub>2</sub> receptors. AM-2201 produces bradycardia and hypothermia in rats at doses of 0.3âÂÂ3 mg/kg, comparable to the potency of JWH-018 in rats, suggesting potent cannabinoid-like activity.
AM-2201 metabolism differs only slightly from that of JWH-018. AM-2201 N-dealkylation produces fluoropentane instead of pentane (or plain alkanes in general).
A forensic standard of AM-2201 is available, and the compound has been posted on the Forendex website of potential drugs of abuse.
In the United States, AM-2201 is a Schedule I controlled substance.